The National Migraine Centre welcomes the news that atogepant has been recommended for use as an acute, rescue treatment for migraine.
Migraine affects 14 per cent of the UK population and, at its worst, can be a severely disabling condition, affecting relationships, employment and mental health. Today’s news will give hope to millions and is yet another breakthrough that, along with other anti-CGRP medications, is revolutionising the treatment of headache.
Dr Katy Munro, senior GP headache specialist at the National Migraine Centre, said: “Migraine is a highly debilitating, genetic, neurological condition which impacts the lives of people who suffer these disabling attacks and also affects their family, friends and colleagues.
“There have been some great developments in how we can help people with migraine over the last few years, and my team at the National Migraine Centre and I welcome the NICE recommendation about the use of atogepant for acute, rescue treatment for migraine attacks. Individuals vary greatly in their response to medications to treat migraine attacks and it is so helpful to have a wider range of options to explore with them now.
“We at the National Migraine Centre always encourage patients to seek information about migraine treatments by looking at our website and our factsheets, listening to our Heads Up podcast or referring themselves to see one of our specialist doctors. I am hopeful that many primary care providers, including pharmacists, will be able to help more people with migraine and that migraine funding, understanding and training is seen as a priority going forward.”
Further information on the work of the charity is available on the National Migraine Centre websites.
